Efficacy and safety of alirocumab once-monthly in patients with atherosclerotic cardiovascular disease and without history of an acute atherothrombotic event

Figures

• 

  Fig. 1. Central Illustration — Efficacy and safety of once-monthly alirocumab 300 mg Q4W versus placebo in participants with established ASCVD without prior ischemic events (ODYSSEY CHOICE I; ITT population, n = 78 alirocumab vs. n = 38 placebo). (A) Percentage change from baseline in calculated LDL-C over time (co-primary endpoints: week 24 and average of weeks 21-24). (B) Proportion of participants achieving LDL-C goals of <70 and <55 mg/dL at week 24. (C) Percentage change from baseline at week 24 in Lp(a), total cholesterol, non-HDL-C, ApoB, and triglycerides. (D) Treatment-emergent adverse events over the 48-week double-blind period. Error bars denote 95% CIs. Efficacy estimates (panels A and C) are least-squares mean (95% CI) from a mixed-effect model with repeated measures; goal attainment (panel B) is the proportion of participants achieving each goal (logistic regression), with 95% CIs; safety comparisons (panel D) by Fisher's exact test. All p-values are nominal and unadjusted for multiplicity. ApoB, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; D/C, discontinuation; HDL-C, high-density lipoprotein cholesterol; ITT,…